Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial.

ABSTRACT:

SUBMITTER: Nywening TM 

PROVIDER: S-EPMC5407285 | biostudies-literature | 2016 May

REPOSITORIES: biostudies-literature